Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering

Pedersen, Terje R. · 2010 · American Journal Cardiovascular Drugs

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are extremely effective at reducing low-density lipoprotein (LDL) cholesterol and have been demonstrated to reduce mortality and the risk of major cardiovascular events in a number of large primary and secondary prevention studies. The linear relationship between LDL-cholesterol and cardiovascular risk suggests statins work solely by reducing LDL-cholesterol, and that ancillary properties do not contribute to cardiovascular risk reduction. In recent years, however, a number of additional non-lipid-lowering, or 'pleiotropic', effects of statins have been suggested to contribute to their efficacy in cardiovascular disease. The first data to suggest that statins may have benefits beyond lipid lowering came from the Heart Protection Study, in which simvastatin reduced mortality and morbidity even in patients with 'normal' LDL-cholesterol levels (2.6 mmol/L or 100 mg/dL). It has since been demonstrated, however, that cardiovascular risk remains high at this LDL concentration, but is substantially reduced in those achieving levels below 2.0 mmol/L (77 mg/dL). Evidence for the pleiotropic effects of statins in heart failure comes largely from retrospective and subgroup analyses of large studies. When statin therapy is compared with placebo, or when high-dose statin therapy is compared with low-dose treatment, a lower incidence of heart failure or hospitalization is observed. Despite promising retrospective data, ho…

Overview

Integrity signals

Registry

Crossref · 10.2165/1158822-s0-000000000-00000

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 48 · Cited by 74

Research works printed but not linked: 1

  1. Leren, 1975, Acta Med Scand Suppl, 588, 1

Metadata

Authors
Pedersen, T. R.
Affiliations
Oslo University Hospital (NO)
Corresponding author
Pedersen, Terje R.
Venue
American Journal Cardiovascular Drugs
Published
2010-12
Volume
10
Pages
10-17
ISSN
1175-3277 (ISSN-L)
OpenAlex
W217155269
Cited by
74
References
48
Citations by year
2026: 2 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 4 · 2013: 11 · 2012: 4
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
statins, pleiotropy, LDL cholesterol lowering, cardiovascular risk reduction, heart failure, endothelial function, atherosclerotic plaque, inflammation, antithrombotic activity, simvastatin, rosuvastatin, torcetrapib
MeSH terms
Animals, Anticholesteremic Agents, Cardiovascular Diseases, Heart Failure, Humans, Cholesterol, LDL, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering. https://app.cochat.ai/papers/10.2165/1158822-s0-000000000-00000
The paper
Pedersen, T. R. (2010). Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering. American Journal Cardiovascular Drugs. https://doi.org/10.2165/1158822-s0-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.